Plexxikon, a member of the Daiichi Sankyo Group, announced today that data related to PLX3397, a novel oral small molecule that potently and selectively inhibits CSF1R, KIT and mutant FLT3 kinases, will be presented in three separate presentations at the 50th American Society of Clinical Oncology (ASCO) 2014 Annual Meeting taking place May 30-June 3, 2014, in Chicago, Illinois.